Article Details
Retrieved on: 2018-02-21 01:13:26
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Dow's Merck (MRK) announced its plan Wednesday to acquire Australian biotech Viralytics in a $394 million deal that dovetails well with the drugmaker's immuno-oncology focus, according to one analyst. X Viralytics is developing a cancer drug called Cavatak. Cavatak is created using a virus that ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here